Treatment of Cancer-Associated Thrombosis: Recent Advances, Unmet Needs, and Future Direction
Authors:
Open Access
- 12 May 2023
- journal article
- research article
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 28 (7) , 555-564
Abstract
Cancer-associated thrombosis, with the incidence rising over the years, is associated with significant morbidity and mortality in patients with cancer. Recent advances in the treatment of cancer-associated venous thromboembolism (VTE) include the introduction of direct oral anticoagulants (DOACs), which provide a more convenient and effective option than low-molecular-weight heparin (LMWH). Nonetheless, important unmet needs remain including an increased risk of bleeding in certain patient subgroups such as those with gastroesophageal cancer, concerns about drug-drug interactions, and management of patients with severe renal impairment. Although DOACs are more convenient than LMWH, persistence can decline over time. Factor XI inhibitors have potential safety advantages over DOACs because factor XI appears to be essential for thrombosis but not hemostasis. In phase II trials, some factor XI inhibitors were superior to enoxaparin for the prevention of VTE after knee replacement surgery without increasing the risk of bleeding. Ongoing trials are assessing the efficacy and safety of factor XI inhibitors for the treatment of cancer-associated VTE.Keywords
Funding Information
- National Heart, Lung, and Blood Institute (U01 HL143402)
- Chinese Academy of Medical Sciences (2021-1-I2M-018)
This publication has 49 references indexed in Scilit:
- New Oral Anticoagulants and the Cancer PatientThe Oncologist, 2013
- Epidemiology of cancer-associated venous thrombosisBlood, 2013
- Associations between cancer‐related financial stress and strain and psychological well‐being among individuals living with cancerPsycho-Oncology, 2012
- Patients with severe factor XI deficiency have a reduced incidence of deep-vein thrombosisThrombosis and Haemostasis, 2011
- Reduced incidence of ischemic stroke in patients with severe factor XI deficiencyBlood, 2008
- Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapyJournal of Thrombosis and Haemostasis, 2007
- Low-Molecular-Weight Heparin versus a Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients with CancerNew England Journal of Medicine, 2003
- Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosisBlood, 2002
- Predictors of Recurrence After Deep Vein Thrombosis and Pulmonary EmbolismArchives of internal medicine (1960), 2000
- High Levels of Coagulation Factor XI as a Risk Factor for Venous ThrombosisNew England Journal of Medicine, 2000